Premium
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing: 2014 Update
Author(s) -
Martin M A,
Hoffman J M,
Freimuth R R,
Klein T E,
Dong B J,
Pirmohamed M,
Hicks J K,
Wilkinson M R,
Haas D W,
Kroetz D L
Publication year - 2014
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2014.38
Subject(s) - dosing , pharmacogenetics , abacavir , guideline , medicine , clinical pharmacology , pharmacology , genotype , family medicine , biology , genetics , human immunodeficiency virus (hiv) , pathology , antiretroviral therapy , viral load , gene
The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing were originally published in April 2012. We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplementary Material online and included additional resources for applying CPIC guidelines to the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).